PEG-based hydrogels with tunable degradation characteristics to control delivery of marrow stromal cells for tendon overuse injuries
Source abstract
Abstract
Marrow stromal cells (MSCs) have been suggested as a means to improve healing in tendon overuse injuries (tendinopathy), but optimal delivery methods for these cells have yet to be determined. In this study novel degradable hydrogels based on oligo(poly(ethylene glycol) fumarate) (OPF) and acrylated poly(ethylene glycol)-dithiothreitol (Ac PEG-DTT) with tunable degradation times ranging from a few days to >1 month were synthesized as MSC carriers for tendon overuse injuries. The addition of higher amounts of OPF or higher dithiothreitol (DTT) concentrations resulted in enhanced fold swelling and degradation. Three formulations, including non-degrading, slower degrading (degraded in ∼10 days) and faster degrading (degraded in ∼5 days) hydrogels were selected for studies with MSCs in tendon tissue explants that had been treated with collagenase as a reproducible model of tendinopathy. Quantitative analysis of the resulting histology images indicated that cell delivery from the hydrogels was dependent on the degradation rate, with cells present in the tissue only after hydrogel dissolution. In addition, significantly more cells were found in the tendon after 14 days with the fast degrading (53±19) vs. slow degrading (20±6) hydrogels. Based on these results, OPF/Ac PEG-DTT hydrogels provide a versatile biomaterial platform to control cell delivery and thus better identify dosing regimens required for MSC-based therapies for tendinopathy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tendon Structure and Treatment · Shoulder Injury and Treatment · Sports injuries and prevention
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. The basic science of tendinopathy10.1007/s11999-008-0286-4 ↗
2. Current concepts review tendon injury and tendinopathy: healing and repair
3. Supraspinatus tendon organizational and mechanical properties in a chronic rotator cuff tear animal model10.1016/j.jbiomech.2003.09.019 ↗
4. Histopathology of common tendinopathies – update and implications for clinical management10.2165/00007256-199927060-00004 ↗
5. Rat supraspinatus tendon expresses cartilage markers with overuse10.1002/jor.20347 ↗
6. Matrix metalloproteases: a role in overuse tendinopathies10.1136/bjsm.2005.017855 ↗
7. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology10.1016/S0945-053X(01)00196-2 ↗
8. Increased deposition of sulfated glycosaminoglycans in human patellar tendinopathy10.1097/JSM.0b013e318037998f ↗
9. Biomechanics of tendon injury and repair10.1016/j.jbiomech.2003.11.005 ↗
10. Treatment of tendinopathy: what works, what does not, and what is on the horizon10.1007/s11999-008-0260-1 ↗
11. Bone marrow-derived mesenchymal stem cells influence early tendon-healing in a rabbit Achilles tendon model10.2106/JBJS.E.01396 ↗
12. Bone marrow stromal cells in a liquid fibrin matrix improve the healing process of patellar tendon window defects10.1089/ten.tea.2008.0046 ↗
13. Bone marrow stromal cells act as feeder cells for tendon fibroblasts through soluble factors10.1089/ten.2006.0079 ↗
14. Mesenchymal stem cell therapy for equine tendinopathy10.1080/09638280701788241 ↗
15. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons10.1002/jor.20887 ↗
16. Young NJ, Dudhia J, Goodship AE, Smith RKM. Mesenchymal progenitor cell therapy for tendon regeneration. 56th ORS Annual Meeting New Orleans; 2010.
17. Cell-based cardiac repair–reflections at the 10-year point10.1161/CIRCULATIONAHA.105.546218 ↗
18. Therapeutic applications of mesenchymal stem cells to repair kidney injury10.1016/j.juro.2010.03.050 ↗
19. Degradative properties and cytocompatibility of a mixed-mode hydrogel containing oligo[poly(ethylene glycol) fumarate] and poly(ethylene glycol)dithiol10.1016/j.actbio.2008.09.015 ↗
20. In vitro cytotoxicity of unsaturated oligo[poly(ethylene glycol) fumarate] macromers and their cross-linked hydrogels10.1021/bm020121m ↗
21. Hammoudi TM, Lu H, Temenoff JS. Long-term spatially defined coculture within three-dimensional photopatterned hydrogels. Tissue Eng Pt C (2010). doi:10.1089/ten.tec.2010.0146.10.1089/ten.tec.2010.0146 ↗
22. An approach to modulate degradation and mesenchymal stem cell behavior in poly(ethylene glycol) networks10.1021/bm701179s ↗
23. An adaptable hydrogel array format for 3-dimensional cell culture and analysis10.1016/j.biomaterials.2008.04.040 ↗
24. Synthesis and characterization of oligo(poly(ethylene glycol) fumarate) macromer10.1021/ma001563y ↗
25. Photolithographic patterning of polyethylene glycol hydrogels10.1016/j.biomaterials.2005.11.045 ↗
26. In vitro osteogenic differentiation of marrow stromal cells encapsulated in biodegradable hydrogels10.1002/jbm.a.30064 ↗
27. Peppas · 1987
28. Regulating activation of transplanted cells controls tissue regeneration10.1073/pnas.0506004103 ↗
29. Designing scaffolds to enhance transplanted myoblast survival and migration10.1089/ten.2006.12.1295 ↗
30. Cell delivery mechanisms for tissue repair10.1016/j.stem.2008.02.005 ↗
31. Material-based deployment enhances efficacy of endothelial progenitor cells10.1073/pnas.0803873105 ↗
32. Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis10.3109/17453670209178031 ↗
33. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins10.1016/j.jconrel.2004.10.029 ↗
34. Towards a fully-synthetic substitute of alginate: development of a new process using thermal gelation and chemical cross-linking10.1016/j.biomaterials.2003.12.015 ↗
35. Fibrillar collagen: the key to vertebrate evolution? A tale of molecular incest10.1002/bies.10230 ↗
36. Animal models of tendinopathy10.1080/09638280701785460 ↗
37. Cytokine-induced tendinitis: a preliminary study in rabbits10.1002/jor.1100170204 ↗
38. Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells10.1089/scd.2006.0032 ↗
39. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities10.1634/stemcells.2007-0054 ↗